SCLC Clinical Trial
Official title:
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05026593 -
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Suspended |
NCT04826341 -
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
| Withdrawn |
NCT04677361 -
Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab
|
Early Phase 1 | |
| Terminated |
NCT00522639 -
Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
|
Phase 3 | |
| Completed |
NCT03428607 -
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
|
Phase 2 | |
| Recruiting |
NCT05546268 -
Study of Oral MRT-2359 in Selected Cancer Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
| Not yet recruiting |
NCT03244904 -
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
|
N/A | |
| Completed |
NCT01713296 -
Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04162041 -
Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05130255 -
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
|
Phase 1 | |
| Recruiting |
NCT04686682 -
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05879068 -
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
|
Phase 2 | |
| Recruiting |
NCT04684017 -
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00346385 -
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02734004 -
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
|
Phase 1/Phase 2 |